Atorvastatin reduces sympathetic activity and increases baroreceptor reflex sensitivity in patients with hypercholesterolaemia and systemic arterial hypertension

Kardiologia Polska

Volumn 67, Issue 6, 2009, Pages 613-620

  Siński, Maciej ^a   Lewandowski, Jacek ^a   Ciarka, Agnieszka ^b   Bidiuk, Joanna ^a   Abramczyk, Piotr ^a   Dobosiewicz, Anna ^a   Gaciong, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Baroreflex sensitivity; Hypercholesterolaemia; Hypertension; Statins; Sympathetic system

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART RATE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; PRESSORECEPTOR REFLEX; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

EID: 67649643260     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256: 2835-2838 (Pubitemid 17178361)
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389 (Pubitemid 24365311)
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335: 1001-1009
4. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307
5. Muldoon MF, Herbert TB, Patterson SM, et al. Effects of acute psychological stress on serum lipid levels, hemoconcentration, and blood viscosity. Arch Int Med 1995; 155: 615-620
6. Jorgensen RS, Nash JK, Lasser NL, et al. Heart rate acceleration and its relationship to total serum cholesterol, triglycerides, triglycerides, and blood pressure reactivity in men with mild hypertension. Psychophysiology 1988; 25: 39-44. (Pubitemid 18044358)
7. Collins R, Armitage J, Parish S, et al.; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
8. Marchesi S, Lupattelli G, Siepi D, et al. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol 2000; 36: 617-621 (Pubitemid 30808051)
9. Martinez-Gonzalez J, Raposo B, Rodriguez C, et al. 3-Hydroxy-3- methylglutaryl coenzyme A reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation. Arterioscler Thromb Vasc Biol 2001; 21: 804-809 (Pubitemid 32454502)
10. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1671-1678 (Pubitemid 28521054)
11. Aviram M, Rosenblat M, Bisgaier CL, et al. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998; 138: 271-279 (Pubitemid 28314098)
12. Joukhadar C, Klein N, Prinz M, et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost 2001; 85: 47-51. (Pubitemid 32050941)
13. Pliquett RU, Cornish KG, Peuler JD, et al. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 2003; 107: 2493-2498 (Pubitemid 36605234)
14. Gao L, Wang W, Li YL, et al. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD (P) H oxidase. Circulation 2005; 112: 1763-1770 (Pubitemid 41368152)
15. Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999; 34: 1281-1286 (Pubitemid 30002395)
16. Nickening G, Baumer AT, Temur Y, et al. Statin-sensitive dysregulated AT1 receptor function and density in hyperholesterolemic men. Circulation 1999; 100: 2131-2134
17. Anderson AE, Sinkey CA, Lawton WJ, et al. Elevated sympathetic activity in borderline hypertensive humans. Evidence from the direct intraneural recordings. Hypertension 1989; 19: 1-11.
18. Esler M, Jennings G, Biviano B, et al. Mechanism of elevated plasma noradrenaline in the course of essential hypertension. J Cardiovasc Pharmacol 1986; 8: S39-43. (Pubitemid 16039090)
19. Somers VK, Mark AL, Abboud FM. Potentiation of sympathetic nerve responses to hypoxia in borderline hypertensive subjects. Hypertension 1988; 11: 608-612 (Pubitemid 18189580)
20. Ciarka A, Najem B, Cuylits N, et al. Effects of peripheral chemoreceptors deactivation on sympathetic activity in heart transplant patients. Hypertension 2005; 45: 894-900. (Pubitemid 40628934)
21. Schultz HD, Li YL. Carotid body function in heart failure. Respir Physiol Neurobiol 2007; 157: 171-185 (Pubitemid 46617445)
22. von Haehling S, Anker SD, Bassenge E. Statins and the role of nitric oxide in chronic heart failure. Heart Fail Rev 2003; 8: 99-106. (Pubitemid 36342293)
23. Owlya R, Vollenweider L, Trueb L, et al. Cardiovascular and sympathetic effects of nitric oxide inhibition at rest and during static exercise in humans. Circulation 1997; 96: 3897-3903 (Pubitemid 27506047)
24. Patterson D, Dick JB, Struthers AD. Intensive statin treatment improves baroreflex sensitivity: another cardioprotective mechanism for statins? Heart 2002; 88: 415-416
25. Vallbo AB, Hagbarth KE, Torebjork HE, et al. Somatosensory, proprioceptive, and sympathetic activity in human peripheral nerves. Physiol Rev 1979; 59: 919-957 (Pubitemid 10191396)
26. Parati G, Di Rienzo M, Bertinieri G. Evaluation of the baroreceptor-heart rate reflex by 24-hour intra-arterial blood pressure monitoring in humans. Hypertension 1988; 12: 214-222 (Pubitemid 18222314)
27. Parati G, Di Rienzo M, Mancia G. How to measure barorefex sensitivity: from the cardiovascular laboratory to daily life. J Hypertens 2000; 18: 7-19. (Pubitemid 30093703)
28. Kishi T, Hirooka Y, Mukai Y, et al. Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats. J Hypertens 2003; 21: 379-386 (Pubitemid 36269710)
29. Pehlivanidis AN, Athyros VG, Demitriadis DS, et al. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 2001; 157: 463-469 (Pubitemid 32710027)
30. Pliquett RU, Cornish KG, Zucker IH. Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol 2003; 95: 700-704 (Pubitemid 36944294)
31. Hamaad A, Sosin M, Lip GY, et al. Short-term adjuvant atorvastatin improves frequency domain indices of heart rate variability in stable systolic heart failure. Cardiovasc Drugs Ther 2005; 19: 183-187 (Pubitemid 41253210)
32. Vrtovec B, Okrajsek R, Golicnik A, et al. Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail 2005; 11: 684-690 (Pubitemid 41797497)
33. Gentlesk PJ, Wiley T, Taylor AJ. A prospective evaluation of the effect of simvastatin on heart rate variability in non-ischemic cardiomyopathy. Am Heart J 2005; 150: 478-483 (Pubitemid 41317617)
34. Welzig CM, Shi DG, Park HJ, et al. Lipid lowering by pravastatin increases parasympathetic modulation of heart rate: Galpha (ia), a possible molecular marker for parasympathetic responsiveness. Circulation 2003; 108: 2743-2746 (Pubitemid 37498974)
35. Mital S, Zhang XP, Zhao G, et al. Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol 2000; 279: 2649-2657 (Pubitemid 32005851)
36. Laufs U, La Fata F, Plutky J, et al. Upregulation of endothelil nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-1135 (Pubitemid 28152885)
37. Wassmann S, Laufs U, Baumer AT, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 2001; 59: 646-654 (Pubitemid 32179945)
38. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273: 24266-24271 (Pubitemid 28435775)
39. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711-2719 (Pubitemid 28294580)
40. Kishi T, Hirooka Y, Kimura Y, et al. Overexpression of eNOS in RVLM improves impaired baroreflex control of heart rate in SHRSP. Hypertension 2003; 41: 255-260 (Pubitemid 36204898)
41. Mortensen LH. Endothelin and the central and peripheral nervous systems: a decade of endothelin research. Clin Exp Pharmacol Physiol 1999; 26: 980-984 (Pubitemid 30004321)
42. Yamada Y, Miyajima E, Tochikubo O, et al. Age related changes in muscle sympathetic nerve activity in essential hypertension. Hypertension 1989; 13: 870-877 (Pubitemid 19157983)
43. Wallin BG, Delius W, Hagbarth KE. Comparison of sympathetic nerve activity in normotensive and hypertensive patients. Circ Res 1973; 33: 9-21.
44. Golomb BA, Dimsdale JE, White HL, et al. Reduction in blood pressure with statins. Arch Intern Med 2008; 168: 721-727